Skip to main content
OpenTrials
Completed

NCT Number: NCT03237923

Evaluation of the EasySense System in Congestive Heart Failure

The EasySense device is a non-invasive device designed to measure lung fluid in patients with Congestive Heart Failure (CHF). This study seeks to evaluate the efficacy of the EasySense system in measuring lung fluid volume.

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

The Ohio State University Wexner Medical Center

Columbus, Ohio, 43210, United States

About this study

Across the globe, Congestive Heart Failure (CHF) continues to be the leading cause of mortality and hospitalizations in the 21st century. Despite advancements, prognosis often remains poor and mortality high. Congestive Heart Failure diagnoses are often characterized by frequent hospitalizations and re-admissions, and early detection of pulmonary edema, a chief characteristic of worsening heart failure, may have positive implications in patients' quality of life and frequency of hospitalizations. The EasySense device is a non-invasive device designed to measure lung fluid in patients with CHF. Similar to ultrasound technology, the device uses radiofrequency waves to assess fluid status. The device is placed on the bare skin of the chest and held in place for approximately 60 seconds to obtain a reading.

This study seeks to evaluate the efficacy of the EasySense system in measuring lung fluid volume. Seventy-five patients are sought for enrollment. Patients will be enrolled during their hospital stay, and will be asked to maintain daily EasySense measurements, in addition to other measurements, for thirty days post-discharge.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Current hospitalization for acute decompensated heart failure requiring IV diuretics or vasoactive drugs
  • NYHA class II-IV
  • Willing and able to participate in index and follow-up measurements
  • Able to speak, read, and write in English
  • Knows how to use a smartphone
  • Preference for patients who undergo a right heart catheterization or continuous pulmonary artery monitoring upon admission or during hospitalization

Exclusion criteria

  • Current or planned treatments with any inotropic agents or mechanical support (LVAD, intra-aortic balloon pump, invasive mechanically assisted ventilation) at time of enrollment
  • Requiring demand pacing
  • Prior heart transplant
  • End-stage renal disease on hemodialysis
  • Physical deformities in the thorax area that may prevent proper application of EasySense device, as assessed by investigator
  • Sign of local rib cage or thoracic lesion or any illness which may be aggravated or cause significant discomfort from application of EasySense device, as assessed by investigator
  • Pregnancy or lactation

Treatment and study plan

EasySense device

Device

Implementation of EasySense device during hospitalization and daily post-discharge for thirty days.

Primary outcomes

  1. Comparison of volume status to EasySense measurements

    Time frame: 30 days

    Patient volume status extracted from medical records will be compared to what the EasySense device measures.

Sponsors and collaborators

Lead sponsor

Ohio State University

Other

Collaborators

  • National Institutes of Health (NIH)
  • University of Memphis

Registry information

Important dates

Study start
2017
Primary completion
2019
Study completion
2020
First posted
Aug 3, 2017
Registry last updated
Feb 5, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.